Keyphrases
Atrial Fibrillation
100%
Stroke Prevention
100%
New Anticoagulants
100%
Ischemic Stroke
40%
Vitamin K Antagonists
40%
Anticoagulation
20%
Antithrombotic Therapy
20%
New Drugs
20%
Clinical Development
20%
Rivaroxaban
20%
Anticoagulants
20%
Drug Interactions
20%
Advanced Stage
20%
Food Interaction
20%
Apixaban
20%
Antithrombotic Agents
20%
Major Risk Factors
20%
Regular Monitoring
20%
Dabigatran
20%
Edoxaban
20%
Anticoagulant Agents
20%
Cardiac Rhythm Disturbances
20%
Alternative Anticoagulants
20%
Factor Xa Inhibitors
20%
Direct Thrombin Inhibitors
20%
Narrow Therapeutic Range
20%
Medicine and Dentistry
Apoplexy
100%
Atrial Fibrillation
100%
Anticoagulant
100%
Vitamin K Antagonist
40%
Brain Ischemia
40%
Clinician
20%
Anticoagulation
20%
Antithrombotic Therapy
20%
Heart Rhythm
20%
Antithrombotic
20%
Drug Interaction
20%
Apixaban
20%
Rivaroxaban
20%
Dabigatran
20%
Edoxaban
20%
Blood Clotting Factor 10a Inhibitor
20%
Direct Thrombin Inhibitor
20%
Antithrombotic Agent
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
100%
Atrial Fibrillation
100%
Cerebrovascular Accident
100%
Brain Ischemia
40%
Antivitamin K
40%
Antithrombotic Therapy
20%
Rivaroxaban
20%
Drug Interaction
20%
Apixaban
20%
Edoxaban
20%
Dabigatran
20%
Blood Clotting Factor 10a Inhibitor
20%
Thrombin Inhibitor
20%
Diseases
20%
Neuroscience
Cerebrovascular Accident
100%
Atrial Fibrillation
100%
Antithrombotic
40%
Brain Ischemia
40%
Vitamin K Antagonist
40%
Rivaroxaban
20%
Blood Clotting Factor 10a
20%
Apixaban
20%
Edoxaban
20%
Dabigatran
20%
Antithrombotic Agents
20%
Direct Thrombin Inhibitor
20%
Risk Factor
20%
Drug Interaction
20%